undamentalytics Newsletter
Sign in

Spyre Therapeutics, Inc. (SYRE) stock

Add to watchlist

Add holding +

NASDAQ: SYRE Nasdaq Biotechnology Next results ~November 3, 2026

Spyre Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 96 sales by directors and officers, last 12 monthsInsider trades
  • Funds192 adding, 76 cuttingOf 65 active managers that changed their stake, 47 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 52% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Spyre Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 66% and a beta of 1.8 against the S&P 500.
  • Insiders selling. 7 insiders sold $443M of stock over the past 365 days and none bought (10% under pre-set trading plans).
  • Heavily shorted. 14.2% of the shares available to trade are sold short (8.0 days of average volume to cover).

Latest results

Earnings per share
-$0.36 against an average estimate of -$0.75: beat by 51.8%
Share reaction
+9.9% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.84

Spyre Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.1%
  • 1 week+2.8%
  • 1 month+2.5%
  • This year+191.5%
  • 1 year+290.5%
  • 5 years-50.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Announcement
  6. Insider trade
  7. Announcement
  8. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Spyre Therapeutics, Inc. valuation models and calculator

No model value for Spyre Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Spyre Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.23 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Spyre Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.84 (range −$1.53 to −$0.67) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.83 −43% — 0%
Next −$3.51 −24% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −3.9% on 90 days ago. In the last 30 days, 9 analysts raised Spyre Therapeutics, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Spyre Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.95 Current fiscal year, 60 days ago: −$2.83 Current fiscal year, 30 days ago: −$2.88 Current fiscal year, 7 days ago: −$2.85 Current fiscal year, Now: −$2.83 −$2.83 Next fiscal year, 90 days ago: −$3.13 Next fiscal year, 60 days ago: −$3.43 Next fiscal year, 30 days ago: −$3.52 Next fiscal year, 7 days ago: −$3.52 Next fiscal year, Now: −$3.51 −$3.51

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.95−$3.13
60 days ago −$2.83−$3.43
30 days ago −$2.88−$3.52
7 days ago −$2.85−$3.52
Now −$2.83−$3.51

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.75 −$0.36 +51.8%
Mar 2026 −$0.65 −$0.74 −13.1%
Dec 2025 −$0.80 −$0.74 +7.2%
Sept 2025 −$0.74 −$0.15 +79.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

18 analysts, Oct 2026
Buy1794%
Hold16%
Sell00%

Monthly trend

  1. Oct 20261618
  2. Sep 20261516
  3. Aug 20261617
  4. Jul 20261617

Counts of recommendations published by analysts covering Spyre Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.2%
of tradable shares
Days to cover
7.98
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.6%
of shares
Employees
125
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
SYRE−40%−91%+91%+8%+41%+192%
Industry peers (median)−35%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SYRE42%42%50%67%50%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SYRE−59%−93%−83%−50%−52%−28%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since April 7, 2016: 99% from April 8, 2016 to June 21, 2023. Getting back needed a 11211% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$22.18 – $108.92
From 52-week high
−12.3%
vs 50-day average
+6.3%
vs 200-day average
+29.9%
Volatility (1 year)
66%
Beta vs S&P 500
1.79

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±9.3%
After a week
7 up, 5 down
typical move ±12.4%
After a month
9 up, 3 down
typical move ±19.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +9.9% +1.6% +8.2% −8.3%
May 5, 2026 +5.6% +2.2% +8.5% +13.5%
April 13, 2026 +24.8% +2.2% +43.1% +46.3%
February 19, 2026 +18.1% +0.5% +17.9% +12.7%
November 4, 2025 −3.9% −0.8% −1.8% +40.9%
October 14, 2025 +17.3% +0.3% +22.9% +23.9%
August 5, 2025 −1.2% +0.3% −1.7% +5.1%
May 8, 2025 +10.9% +0.6% +14.4% +35.0%
February 27, 2025 +3.7% −0.1% +7.9% −5.6%
January 13, 2025 −7.4% +0.3% −0.8% +3.6%
November 7, 2024 +5.6% +1.2% −16.6% −28.5%
August 7, 2024 −3.0% +1.6% −5.0% +7.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$8.5B
Institutions reporting
263
Shares held vs prior quarter
▲ 15.7%
Positions opened / closed
89 / 21

Top buyers and sellers, Q2 2026: 192 institutions bought and 76 sold ; the biggest buyer was Paradigm Biocapital Advisors LP (+1.9M shares) and the biggest seller Fairmount Funds Management LLC (−4.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $1.2B 13.0M 13.6% ▲ 10.6%
Blackrock, Inc. $578M 6.5M 6.8% ▲ 17.8%
Perceptive Advisors LLC $383M 4.3M 4.5% ▲ 14.2%
RTW Investments, LP $377M 4.3M 4.4% ▲ 1.9%
Paradigm Biocapital Advisors LP $341M 3.8M 4.0% ▲ 96.2%
Vanguard Capital Management LLC $306M 3.4M 3.6% ▲ 12.8%
State Street Corp $271M 3.1M 3.2% ▲ 17.3%
Venrock Adviser, LLC $265M 3.0M 3.1% ▼ 19.0%
Price T Rowe Associates Inc $263M 3.0M 3.1% ▲ 85.2%
Driehaus Capital Management LLC $249M 2.8M 2.9% ▲ 0.3%
Geode Capital Management, LLC $239M 2.6M 2.8% ▲ 48.9%
Vanguard Portfolio Management LLC $207M 2.3M 2.4% ▲ 298.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Spyre Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $443M 96 trades by 7 insiders · 10% under pre-set plans
Net ▼ $443M net selling
Insider Date Trade Shares Price Value
Burrows Scott L Chief Financial Officer October 1, 2026 Sell pre-set plan 229 $93.57 $21,428
Burrows Scott L Chief Financial Officer October 1, 2026 Sell pre-set plan 3,071 $92.95 $285,449
Burrows Scott L Chief Financial Officer October 1, 2026 Sell pre-set plan 2,100 $91.92 $193,032
Burrows Scott L Chief Financial Officer October 1, 2026 Sell pre-set plan 1,500 $90.27 $135,405
Burrows Scott L Chief Financial Officer October 1, 2026 Sell pre-set plan 600 $89.07 $53,442
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 100 $93.91 $9,391
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 4,990 $93.37 $465,916
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 3,989 $92.31 $368,225
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 2,638 $91.49 $241,351
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 2,683 $90.10 $241,738
Turtle Cameron Chief Executive Officer October 1, 2026 Sell pre-set plan 600 $89.14 $53,484
King-Jones Heidy See Remarks October 1, 2026 Sell pre-set plan 2,600 $93.46 $242,996

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 13, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • April 13, 2026
  • February 19, 2026
  • November 4, 2025
  • October 14, 2025

Recent SEC filings

Data status

When each part of this page on Spyre Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Spyre Therapeutics, Inc. in brief

What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Spyre Therapeutics, Inc.'s stock ticker?
Spyre Therapeutics, Inc. trades under the ticker SYRE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Spyre Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Perceptive Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Spyre Therapeutics, Inc. stock?
Over the last 12 months, Spyre Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 96 sales on Form 4. The insider trading page charts every trade.
When is Spyre Therapeutics, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Spyre Therapeutics, Inc. announces its own schedule.